Grant LR, Slack MPE, Yan Q, Trzcinski K, Barratt J, Sobczyk E, et al. The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. Expert Rev Vaccines. 2021;20(6):691–705.

Article  CAS  PubMed  Google Scholar 

Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–12.

Article  PubMed  Google Scholar 

Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: the role of risk stacking. Open Forum Infect Dis. 2015;2(1):ofv020.

Article  PubMed  PubMed Central  Google Scholar 

Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831–8.

Article  CAS  PubMed  Google Scholar 

Centers for Disease Control and Prevention. Pneumococcal disease: risk factors and transmission 2022 [March 3, 2022]. 2020. Available from: https://www.cdc.gov/pneumococcal/about/risk-transmission.html. Accessed 3 Mar 2022.

Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816–9.

Google Scholar 

Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Almirall J, Serra-Prat M, Bolibar I, Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration. 2017;94(3):299–311.

Article  PubMed  Google Scholar 

Fedson DS, Baldwin JA. Previous hospital care as a risk factor for pneumonia. Implications for immunization with pneumococcal vaccine. JAMA. 1982;248(16):1989–95.

Article  CAS  PubMed  Google Scholar 

Aul DR, Gates DJ, Draper DA, Dunleavy DA, Ruickbie DS, Meredith DH, et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med. 2021;188:106602.

Article  PubMed  PubMed Central  Google Scholar 

Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4(1):e2036142.

Article  PubMed  PubMed Central  Google Scholar 

Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, Polici M, Rucci C, Bracci B, Nicolai M, Cremona A, De Dominicis C, Laghi A. Post-acute sequelae of COVID-19 pneumonia: six-month chest CT follow-up. Radiology. 2021;301(2):E396–E405. https://doi.org/10.1148/radiol.2021210834.

Fraser E. Persistent pulmonary disease after acute covid-19. BMJ. 2021;373:n1565.

Article  PubMed  Google Scholar 

Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah AS, Wong AW, Hague CJ, Murphy DT, Johnston JC, Ryerson CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402–4.

Article  PubMed  Google Scholar 

Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27(4):328–37.

Article  CAS  PubMed  Google Scholar 

Writing Committee for the Comebac Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325(15):1525–34.

Article  Google Scholar 

Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon JJ, Heyman B, Ko JP, Condos R, Lynch DA. CT of post-acute lung complications of COVID-19. Radiology. 2021;301(2):E383–E395. https://doi.org/10.1148/radiol.2021211396.

Murthy N, Wodi AP, Bernstein H, Ault KA, Advisory Committee on Immunization P. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175(3):432–43.

Article  PubMed  Google Scholar 

Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, et al. The Advisory Committee on Immunization Practices’ interim recommendations for additional primary and booster doses of COVID-19 vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1545–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41.

Article  PubMed  PubMed Central  Google Scholar 

Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775–82.

Article  PubMed  PubMed Central  Google Scholar 

Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥ years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewnard JA, Bruxvoort KJ, Fischer H, Hong VX, Grant LR, Jodar L, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against medically attended lower respiratory tract infection and pneumonia among older adults. Clin Infect Dis. 2022;75(5):832–41.

Article  CAS  PubMed  Google Scholar 

Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192(5):597–604.

Article  PubMed  Google Scholar 

Dang TT, Eurich DT, Weir DL, Marrie TJ, Majumdar SR. Rates and risk factors for recurrent pneumonia in patients hospitalized with community-acquired pneumonia: population-based prospective cohort study with 5 years of follow-up. Clin Infect Dis. 2014;59(1):74–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Vidal C, Carratala J, Fernandez-Sabe N, Dorca J, Verdaguer R, Manresa F, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15(11):1033–8.

Article  CAS  PubMed  Google Scholar 

Dang TT, Majumdar SR, Marrie TJ, Eurich DT. Recurrent pneumonia: a review with focus on clinical epidemiology and modifiable risk factors in elderly patients. Drugs Aging. 2015;32(1):13–9.

Article  CAS  PubMed  Google Scholar